MedTrace Logo

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

NCT06044467 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-09-21

No results posted yet for this study

Summary

A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) \< 3 that are in general good health and have normal liver functions to be treated with CM-101.

Conditions

  • Nonalcoholic Fatty Liver Disease

Interventions

DRUG

Anti-human CCL24 monoclonal antibody (CM-101) - Part One

Anti-human CCL24 monoclonal antibody (CM-101) - Part One

DRUG

Anti-human CCL24 monoclonal antibody (CM-101) - Part Two

Anti-human CCL24 monoclonal antibody (CM-101) - Part Two

DRUG

Placebo - Study Part One

Placebo Comparator

DRUG

Placebo - Study Part Two

Placebo Comparator

Sponsors & Collaborators

  • ChemomAb Ltd.

    lead INDUSTRY

Principal Investigators

  • Arnon Aharon, MD · ChemomAb Ltd.

  • Rifaat Safadi, MD · Hadassah University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-11
Primary Completion
2020-04-27
Completion
2020-04-27

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06044467 on ClinicalTrials.gov